1. Home
  2. Investing
  3. Stocks
  4. USA
  6. CytoSorbents Corporation (CTSO)
  7. Quote


CytoSorbents Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Regular Market
Volume 30,207
Bid Price 5.81
Ask Price 5.84
News -
Day High 5.88


52 Week Range


Day Low 5.80
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CytoSorbents Corporation CTSO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 5.83 10:26:51
Open Price Low Price High Price Close Price Prev Close
5.80 5.80 5.88 5.83
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
142 30,207 $ 5.84 $ 176,357 - 5.7348 - 11.684
Last Trade Time Type Quantity Stock Price Currency
10:26:51 100 $ 5.83 USD


Draw Mode:

CytoSorbents Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 251.61M 43.16M 31.77M $ 41.00M $ -11.43M -0.59 -22.01
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 3.00 65.20%

more financials information »

CytoSorbents News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTSO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.996.285.73485.94253,711-0.16-2.67%
1 Month8.098.235.73486.51323,533-2.26-27.94%
3 Months7.229.805.73487.70298,317-1.39-19.25%
6 Months9.109.805.73487.92266,873-3.27-35.93%
1 Year8.2011.6845.73488.58286,046-2.37-28.9%
3 Years10.1913.893.497.81331,891-4.36-42.79%
5 Years5.8514.953.307.92267,316-0.02-0.34%

CytoSorbents Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.